MABBI – Research conducted by Lekshmi Rethi, Chinmaya Mutalik, Dito Anurogo, Long-Sheng L, Hsiu-Yi Chu, Sibidou Yougbaré, Tsung-Rong Kuo, Tsai-Mu Cheng, and Fu-Lun Chen from Taipei Medical University, Taipei 11031, Taiwan. Universitas Muhammadiyah Makassar, Makassar City 90221, South Sulawesi, Indonesia, Institut de Recherche en Sciences de la Santé/Direction Régionale du Centre Ouest (IRSS/DRCO), Nanoro BP 218, 11, Burkina Faso entitled Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy.
Globally, breast cancer is one of the most prevalent diseases, inducing critical intimidation to human health. Lipid-based nanomaterials have been successfully demonstrated as drug carriers for breast cancer treatment. To date, the development of a better drug delivery system based on lipid nanomaterials is still urgent to make the treatment and diagnosis easily accessible to breast cancer patients. In a drug delivery system, lipid nanomaterials have revealed distinctive features, including high biocompatibility and efficient drug delivery. Specifically, a targeted drug delivery system based on lipid nanomaterials has inherited the advantage of optimum dosage and low side effects. In this review, insights on currently used potential lipid-based nanomaterials are collected and introduced. The review sheds light on conjugation, targeting, diagnosis, treatment, and clinical significance of lipid-based nanomaterials to treat breast cancer. Furthermore, a brighter side of lipid-based nanomaterials as future potential drug delivery systems for breast cancer therapy is discussed. (Tri/MABBI)
Read more: https://pubmed.ncbi.nlm.nih.gov/36079985/
Leave a Reply